Matt Miksic
Stock Analyst at Barclays
(3.44)
# 951
Out of 5,240 analysts
359
Total ratings
53.02%
Success rate
2.3%
Average return
Main Sectors:
Stocks Rated by Matt Miksic
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Maintains: Overweight | $12 → $13 | $4.09 | +217.85% | 5 | May 13, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $56 → $55 | $14.50 | +279.31% | 9 | May 11, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $202 → $204 | $144.75 | +40.93% | 3 | May 11, 2026 | |
| PODD Insulet | Maintains: Underweight | $286 → $198 | $148.67 | +33.18% | 13 | May 8, 2026 | |
| ALC Alcon | Maintains: Equal-Weight | $90 → $78 | $63.65 | +22.55% | 12 | May 8, 2026 | |
| LIVN LivaNova | Maintains: Equal-Weight | $73 → $76 | $72.49 | +4.84% | 11 | May 7, 2026 | |
| INMD InMode | Maintains: Overweight | $21 → $19 | $13.97 | +36.01% | 15 | May 7, 2026 | |
| ATEC Alphatec Holdings | Maintains: Overweight | $27 → $24 | $7.60 | +215.79% | 6 | May 7, 2026 | |
| SYK Stryker | Maintains: Overweight | $469 → $394 | $300.55 | +31.09% | 25 | May 4, 2026 | |
| BAX Baxter International | Maintains: Overweight | $25 → $27 | $17.62 | +53.23% | 25 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $72 → $67 | $57.79 | +15.95% | 11 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $87 → $78 | $62.67 | +24.46% | 3 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $94 | $82.40 | +14.08% | 11 | Apr 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $110 | $81.11 | +35.63% | 33 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $712 → $651 | $432.31 | +50.59% | 10 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $96 | $53.01 | +81.10% | 22 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $144 → $143 | $84.88 | +68.47% | 34 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $234 → $255 | $230.34 | +10.71% | 17 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $1.5 | $1.03 | +45.63% | 2 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $118 → $120 | $76.62 | +56.62% | 26 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $11.14 | +133.39% | 1 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $98 → $103 | $60.52 | +70.19% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $118 → $123 | $76.19 | +61.44% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $20 | $16.26 | +23.00% | 7 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1.5 → $31 | $5.69 | +444.82% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $6.76 | +225.44% | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $100 | $71.28 | +40.29% | 8 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $722 → $418 | $160.89 | +159.80% | 3 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $28 | $15.44 | +81.35% | 2 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $67 | $10.65 | +529.11% | 1 | Mar 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $87 | $14.72 | +491.03% | 14 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $2.74 | +812.41% | 5 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $24 | - | - | 1 | Oct 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $9 | $3.57 | +152.45% | 1 | Dec 12, 2016 |
Orchestra BioMed Holdings
May 13, 2026
Maintains: Overweight
Price Target: $12 → $13
Current: $4.09
Upside: +217.85%
Tandem Diabetes Care
May 11, 2026
Maintains: Overweight
Price Target: $56 → $55
Current: $14.50
Upside: +279.31%
Becton, Dickinson and Company
May 11, 2026
Maintains: Overweight
Price Target: $202 → $204
Current: $144.75
Upside: +40.93%
Insulet
May 8, 2026
Maintains: Underweight
Price Target: $286 → $198
Current: $148.67
Upside: +33.18%
Alcon
May 8, 2026
Maintains: Equal-Weight
Price Target: $90 → $78
Current: $63.65
Upside: +22.55%
LivaNova
May 7, 2026
Maintains: Equal-Weight
Price Target: $73 → $76
Current: $72.49
Upside: +4.84%
InMode
May 7, 2026
Maintains: Overweight
Price Target: $21 → $19
Current: $13.97
Upside: +36.01%
Alphatec Holdings
May 7, 2026
Maintains: Overweight
Price Target: $27 → $24
Current: $7.60
Upside: +215.79%
Stryker
May 4, 2026
Maintains: Overweight
Price Target: $469 → $394
Current: $300.55
Upside: +31.09%
Baxter International
May 4, 2026
Maintains: Overweight
Price Target: $25 → $27
Current: $17.62
Upside: +53.23%
May 1, 2026
Maintains: Underweight
Price Target: $72 → $67
Current: $57.79
Upside: +15.95%
Apr 30, 2026
Maintains: Equal-Weight
Price Target: $87 → $78
Current: $62.67
Upside: +24.46%
Apr 29, 2026
Maintains: Underweight
Price Target: $100 → $94
Current: $82.40
Upside: +14.08%
Apr 27, 2026
Maintains: Overweight
Price Target: $104 → $110
Current: $81.11
Upside: +35.63%
Apr 23, 2026
Maintains: Overweight
Price Target: $712 → $651
Current: $432.31
Upside: +50.59%
Apr 23, 2026
Maintains: Overweight
Price Target: $100 → $96
Current: $53.01
Upside: +81.10%
Apr 20, 2026
Maintains: Overweight
Price Target: $144 → $143
Current: $84.88
Upside: +68.47%
Apr 15, 2026
Maintains: Equal-Weight
Price Target: $234 → $255
Current: $230.34
Upside: +10.71%
Apr 8, 2026
Maintains: Overweight
Price Target: $3.5 → $1.5
Current: $1.03
Upside: +45.63%
Apr 1, 2026
Maintains: Overweight
Price Target: $118 → $120
Current: $76.62
Upside: +56.62%
Apr 1, 2026
Initiates: Overweight
Price Target: $26
Current: $11.14
Upside: +133.39%
Mar 6, 2026
Maintains: Overweight
Price Target: $98 → $103
Current: $60.52
Upside: +70.19%
Feb 25, 2026
Maintains: Overweight
Price Target: $118 → $123
Current: $76.19
Upside: +61.44%
Feb 19, 2026
Maintains: Equal-Weight
Price Target: $17 → $20
Current: $16.26
Upside: +23.00%
Nov 5, 2025
Maintains: Overweight
Price Target: $1.5 → $31
Current: $5.69
Upside: +444.82%
Jan 7, 2025
Initiates: Overweight
Price Target: $22
Current: $6.76
Upside: +225.44%
May 13, 2022
Assumes: Outperform
Price Target: $100
Current: $71.28
Upside: +40.29%
May 4, 2022
Maintains: Outperform
Price Target: $722 → $418
Current: $160.89
Upside: +159.80%
Mar 2, 2022
Maintains: Outperform
Price Target: $31 → $28
Current: $15.44
Upside: +81.35%
Mar 1, 2022
Maintains: Outperform
Price Target: $68 → $67
Current: $10.65
Upside: +529.11%
Nov 3, 2021
Maintains: Outperform
Price Target: $84 → $87
Current: $14.72
Upside: +491.03%
Aug 10, 2021
Maintains: Outperform
Price Target: $24 → $25
Current: $2.74
Upside: +812.41%
Oct 10, 2017
Maintains: Buy
Price Target: $26 → $24
Current: -
Upside: -
Dec 12, 2016
Initiates: Sell
Price Target: $9
Current: $3.57
Upside: +152.45%